DK3160966T3 - Mnk-inhibitorer og fremgangsmåder forbundet dermed - Google Patents

Mnk-inhibitorer og fremgangsmåder forbundet dermed Download PDF

Info

Publication number
DK3160966T3
DK3160966T3 DK15742147.0T DK15742147T DK3160966T3 DK 3160966 T3 DK3160966 T3 DK 3160966T3 DK 15742147 T DK15742147 T DK 15742147T DK 3160966 T3 DK3160966 T3 DK 3160966T3
Authority
DK
Denmark
Prior art keywords
mnk inhibitors
methods concerned
concerned
methods
mnk
Prior art date
Application number
DK15742147.0T
Other languages
English (en)
Inventor
Paul A Sprengeler
Stephen E Webber
Alan Xin Xiang
Justin Thomas Ernst
Siegfried H Reich
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Application granted granted Critical
Publication of DK3160966T3 publication Critical patent/DK3160966T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
DK15742147.0T 2014-06-25 2015-06-24 Mnk-inhibitorer og fremgangsmåder forbundet dermed DK3160966T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017112P 2014-06-25 2014-06-25
PCT/US2015/037416 WO2015200481A1 (en) 2014-06-25 2015-06-24 Mnk inhibitors and methods related thereto

Publications (1)

Publication Number Publication Date
DK3160966T3 true DK3160966T3 (da) 2019-05-27

Family

ID=53724447

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15742147.0T DK3160966T3 (da) 2014-06-25 2015-06-24 Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK19158973.8T DK3521289T3 (da) 2014-06-25 2015-06-24 Mnk-inhibitorer og fremgangsmåder forbundet dermed

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19158973.8T DK3521289T3 (da) 2014-06-25 2015-06-24 Mnk-inhibitorer og fremgangsmåder forbundet dermed

Country Status (24)

Country Link
US (6) US9382248B2 (da)
EP (2) EP3160966B1 (da)
JP (2) JP6615797B2 (da)
KR (1) KR102460389B1 (da)
CN (2) CN110183449B (da)
AU (1) AU2015279984B2 (da)
BR (1) BR112016029916B1 (da)
CA (1) CA2953365C (da)
CL (1) CL2016003293A1 (da)
CO (1) CO2017000399A2 (da)
DK (2) DK3160966T3 (da)
EA (1) EA033920B1 (da)
ES (1) ES2728201T3 (da)
FI (1) FI3521289T3 (da)
IL (1) IL249557B (da)
MX (1) MX2016017030A (da)
MY (1) MY189363A (da)
NZ (1) NZ728007A (da)
PE (1) PE20170321A1 (da)
PH (1) PH12016502504A1 (da)
SG (2) SG10201811384TA (da)
TW (1) TWI713455B (da)
WO (1) WO2015200481A1 (da)
ZA (1) ZA201700241B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
JP6681919B2 (ja) * 2015-04-20 2020-04-15 イーフェクター セラピューティクス， インコーポレイテッド がんおよび感染症を処置する際に使用するための免疫チェックポイントモジュレーターの阻害剤
CA3002558A1 (en) 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
BR112018008714A2 (pt) 2015-10-29 2018-10-30 Effector Therapeutics Inc inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
WO2017117052A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
AU2017364901A1 (en) 2016-11-28 2019-06-13 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018134335A1 (en) 2017-01-20 2018-07-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
TW201831479A (zh) 2017-01-20 2018-09-01 德商拜耳製藥公司 經取代二氫咪唑并吡啶二酮
WO2018148745A1 (en) * 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
CN110719781A (zh) 2017-02-14 2020-01-21 效应治疗股份有限公司 取代的哌啶MnK抑制剂及其相关方法
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
AU2018352695A1 (en) 2017-10-19 2020-05-28 Effector Therapeutics, Inc. Benzimidazole-indole inhibitors of Mnk1 and Mnk2
AU2019278814A1 (en) 2018-05-30 2020-12-17 Praxis Precision Medicines, Inc. Ion channel modulators
EP3870178A4 (en) 2018-10-24 2022-08-03 Effector Therapeutics Inc. CRYSTALLINE FORMS OF MNK INHIBITORS
WO2020108619A1 (zh) * 2018-11-30 2020-06-04 上海迪诺医药科技有限公司 Mnk抑制剂
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
EP3972593A4 (en) * 2019-05-23 2023-06-28 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
BR112021026682A2 (pt) 2019-07-02 2022-03-15 Effector Therapeutics Inc Compostos e métodos para inibir eif4e
WO2021001743A1 (en) 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translation inhibitors and uses thereof
EP3997089A4 (en) * 2019-07-21 2023-08-16 University Of Virginia Patent Foundation CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF
MX2022005951A (es) * 2019-11-18 2022-07-27 Jumbo Drug Bank Co Ltd Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
MX2022016516A (es) * 2020-06-30 2023-03-28 4E Therapeutics Inc Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso.
EP4200296A1 (en) * 2020-08-20 2023-06-28 Hepagene Therapeutics (HK) Limited Mnk inhibitors
US11925642B2 (en) 2020-10-08 2024-03-12 Board Of Regents, The University Of Texas System Regulation of eIF4E activity for migraine therapy
CN117355528A (zh) * 2021-05-08 2024-01-05 成都嘉葆药银医药科技有限公司 吡咯并三嗪类化合物的盐型、其晶型及其制备方法
KR20240027769A (ko) * 2021-06-30 2024-03-04 4이 테라퓨틱스, 인크. Mnk 억제를 나타내는 스피로사이클릭 피리딘-1,5-디온 및 이의 사용 방법
IL310590A (en) * 2021-08-05 2024-04-01 4E Therapeutics Inc Methods of treating migraine with MNK inhibitors
CN114853756B (zh) * 2022-03-31 2023-03-28 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备工艺
CN114736205B (zh) * 2022-03-31 2023-03-03 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备方法
CN114671869B (zh) * 2022-03-31 2023-06-30 武汉九州钰民医药科技有限公司 化合物Tomivosertib的合成方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491144A (en) 1991-05-30 1996-02-13 Ciba-Geigy Corporation Substituted diaminophthalimides and analogues
US9357797B2 (en) * 1999-11-06 2016-06-07 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
EP1401449B1 (en) * 2001-06-05 2007-04-25 Lilly Icos LLC Tetracyclic compounds as pde5-inhibitors
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2007021308A1 (en) 2005-08-12 2007-02-22 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
WO2007147874A1 (en) * 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
DK2134689T3 (da) 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
UY32072A (es) * 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8609676B2 (en) 2009-08-04 2013-12-17 Merck Sharp & Dohme, Corp. 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
KR20130099117A (ko) 2010-10-01 2013-09-05 바이엘 인텔렉쳐 프로퍼티 게엠베하 치환된 ｎ-(2-아릴아미노)아릴 설폰아미드 함유 배합물
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9447087B2 (en) 2011-09-23 2016-09-20 University Of Utah Research Foundation Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders
JP5797345B2 (ja) 2011-12-30 2015-10-21 ハンミ ファーム． シーオー．， エルティーディー． プロテインキナーゼに対する阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
CN104470926A (zh) * 2012-05-21 2015-03-25 拜耳医药股份有限公司 取代的吡咯并嘧啶
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014072244A1 (en) * 2012-11-09 2014-05-15 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
GB2508652A (en) 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CN105143227A (zh) 2013-02-20 2015-12-09 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1,2-b]哒嗪类化合物
TW201605867A (zh) 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
BR112017013148A2 (pt) * 2014-12-19 2019-11-19 Bayer Pharma AG pirazolopiridinaminas como inibidores mknk1 e mknk2
CA3002558A1 (en) 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
BR112018008714A2 (pt) 2015-10-29 2018-10-30 Effector Therapeutics Inc inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2
GB201520500D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds

Also Published As

Publication number Publication date
SG11201610511YA (en) 2017-01-27
JP6615797B2 (ja) 2019-12-04
CL2016003293A1 (es) 2017-09-08
EP3160966B1 (en) 2019-02-27
NZ728007A (en) 2023-03-31
ES2728201T3 (es) 2019-10-22
US20210338673A1 (en) 2021-11-04
ZA201700241B (en) 2022-05-25
WO2015200481A1 (en) 2015-12-30
CN110183449A (zh) 2019-08-30
CN106795162A (zh) 2017-05-31
EP3160966A1 (en) 2017-05-03
EP3521289B1 (en) 2023-10-25
JP6979439B2 (ja) 2021-12-15
US20170266185A1 (en) 2017-09-21
EP3521289A1 (en) 2019-08-07
IL249557A0 (en) 2017-02-28
CN110183449B (zh) 2022-08-19
WO2015200481A8 (en) 2016-06-30
EA201790078A1 (ru) 2017-05-31
CA2953365C (en) 2023-08-08
CO2017000399A2 (es) 2017-04-28
BR112016029916A2 (pt) 2017-08-22
FI3521289T3 (fi) 2024-01-09
EA033920B1 (ru) 2019-12-10
MY189363A (en) 2022-02-07
US20150376181A1 (en) 2015-12-31
KR20170023145A (ko) 2017-03-02
AU2015279984A1 (en) 2017-01-19
BR112016029916B1 (pt) 2023-12-12
US9814718B2 (en) 2017-11-14
IL249557B (en) 2021-10-31
TWI713455B (zh) 2020-12-21
US20160317536A1 (en) 2016-11-03
US20180085368A1 (en) 2018-03-29
TW201613918A (en) 2016-04-16
US9382248B2 (en) 2016-07-05
SG10201811384TA (en) 2019-01-30
JP2020063251A (ja) 2020-04-23
MX2016017030A (es) 2017-09-11
JP2017519782A (ja) 2017-07-20
KR102460389B1 (ko) 2022-10-27
PH12016502504A1 (en) 2017-04-10
US20190209560A1 (en) 2019-07-11
CA2953365A1 (en) 2015-12-30
PE20170321A1 (es) 2017-04-05
CN106795162B (zh) 2019-07-16
DK3521289T3 (da) 2024-01-15
US9669031B2 (en) 2017-06-06
AU2015279984B2 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
DK3160966T3 (da) Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3205650T3 (da) Egfr-hæmmer og fremstilling og anvendelse deraf
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3380101T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3172213T3 (da) Makrocykliske kinasehæmmere og anvendelser deraf
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3201351T3 (da) Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3212189T3 (da) Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3193611T3 (da) Mk2-inhibitorer og anvendelser deraf
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
BR112016019548A2 (pt) Dispositivo de cálculo de auto-localização e metodo de cálculo de auto-localização
BR112016027102A2 (pt) método e aparelho
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3142659T3 (da) Hiv-1 proteasehæmmere og anvendelser deraf
KR20180084959A (ko) 파면 분석을 위한 디바이스 및 방법
DK3183201T3 (da) Spilsamling og fremgangsmåde til anvendelse
DK3146320T3 (da) Detekteringsanordning og fremgangsmåde
DK3240821T3 (da) Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde
DK3205015T3 (da) Forstærkerkredsløb og fremgangsmåde